RT Journal Article
SR Electronic
T1 Hepatic Angiosarcoma: Clinicopathologic Study With an Investigation of ROS1 Gene Rearrangements
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 1463
OP 1467
DO 10.21873/invivo.11930
VO 34
IS 3
A1 JUNG, HERA
A1 KIM, HAN-NA
A1 JANG, YUNJEONG
A1 PARK, CHEOL-KEUN
A1 SHIN, SO-HYUN
A1 HA, SANG YUN
YR 2020
UL http://iv.iiarjournals.org/content/34/3/1463.abstract
AB Background/Aim: Primary hepatic angiosarcoma (PHA) is a rare disease entity with variable morphologic features. Recent findings regarding ROS1 gene rearrangements in PHA may lead to new targeted therapies. Patients and Methods: Thirteen cases (4 resected specimens and 9 biopsy samples) underwent histologic review and morphologic patterns were classified according to a previous study as 1) sinusoidal, 2) peliotic, 3) vasoformative, and 4) solid (epithelioid/spindled). ROS1 immunohistochemistry and investigation of the presence of a ROS1 fusion gene by reverse transcription-polymerase chain reaction were performed in available cases. Results: Eight of 13 cases (62%) showed vasoformative patterns. Three cases (23%) were classified as sinusoidal and two (15%) as solid patterns. Mortality rate was 90% (9/10) except for three patients lost in follow up. Only one patient is still alive and has survived for 8 months with the disease. All cases tested did not have ROS1 expression (0/9) or a ROS1 fusion gene (0/4). Conclusion: We report 13 cases of PHA with 90% mortality. Vasoformative PHA is the most common histologic type. New findings on ROS1 fusion gene rearrangements could lead to the development of novel targeted therapeutics for PHA patients with dismal prognosis.